Cancer combo trial pulled before it even started
NCT ID NCT07137390
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test two drugs, regorafenib and lorigerlimab, given before surgery to people with colorectal cancer that had spread only to their lungs. The goal was to see if the combination was safe and could help shrink tumors. However, the trial was withdrawn before any participants were enrolled, so no data was collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- regorafenib and lorigerlimab
- What this could lead to
- If it had worked, this combination might have offered a new treatment option before surgery for people with colorectal cancer that spread only to the lungs.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no results are available. The approach was still very early-stage and unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?